Guardant Health, Inc. (NASDAQ:GH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have received a consensus rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $40.00.

A number of research firms recently weighed in on GH. Citigroup boosted their price target on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Piper Sandler raised their price target on Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Leerink Partners reduced their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Sanford C. Bernstein lowered their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday.

Guardant Health Stock Down 5.2 %

NASDAQ:GH opened at $21.88 on Friday. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -5.58 and a beta of 1.11. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. The stock’s fifty day moving average price is $23.39 and its two-hundred day moving average price is $25.64. Guardant Health has a 52-week low of $15.81 and a 52-week high of $37.04.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The firm had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. Guardant Health’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.67) EPS. On average, analysts anticipate that Guardant Health will post -3.31 EPS for the current year.

Institutional Trading of Guardant Health

A number of institutional investors have recently made changes to their positions in GH. JNBA Financial Advisors bought a new stake in Guardant Health during the third quarter worth about $26,000. Quarry LP acquired a new position in shares of Guardant Health during the 2nd quarter worth approximately $44,000. Canton Hathaway LLC bought a new stake in shares of Guardant Health during the 2nd quarter worth approximately $59,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $71,000. Finally, Byrne Asset Management LLC bought a new position in shares of Guardant Health in the second quarter valued at $77,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.